BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 29544351)

  • 1. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line treatments of small-cell lung cancers.
    Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
    Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
    Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
    Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of targeted and immune therapies in SCLC.
    Hendriks LEL; Menis J; Reck M
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
    [No Abstract]   [Full Text] [Related]  

  • 9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and challenges in the treatment of small cell lung cancer.
    Tartarone A; Giordano P; Lerose R; Rodriquenz MG; Conca R; Aieta M
    Med Oncol; 2017 Jun; 34(6):110. PubMed ID: 28456992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment advances in small cell lung cancer (SCLC).
    Waqar SN; Morgensztern D
    Pharmacol Ther; 2017 Dec; 180():16-23. PubMed ID: 28579387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
    Yu L; Lai Q; Gou L; Feng J; Yang J
    J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new hope: the immunotherapy in small cell lung cancer.
    Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
    Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
    Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
    Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.
    Demedts IK; Vermaelen KY; van Meerbeeck JP
    Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.